Biometry
Biometry (myBiometry) is a US-based health technology company developing fenoTRACK, a pre-commercial at-home FeNO breath test device with companion app and predictive engine, targeting asthma and COPD patients, clinicians, payers, and pharmaceutical companies.
- Company typePrivate
- Founded2017
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Biometry does
Biometry Inc. (dba myBiometry) is a US-based health technology company developing diagnostic and remote monitoring tools for patients with chronic respiratory conditions, primarily asthma and COPD. Its core product, fenoTRACK, is a pre-commercial medical device system comprising a portable handheld sensor, single-use test strips, and a companion mobile application that measures fractional exhaled nitric oxide (FeNO) in exhaled breath as a biomarker for type 2 airway inflammation. Device readings, combined with clinical and environmental risk factors collected through the app, are fed into a proprietary "Prediction Engine" intended to generate personalized risk models that anticipate asthma and COPD exacerbations up to 20 days in advance. The company is pursuing FDA regulatory clearance for fenoTRACK and has not yet commercialized the product.
The business model is a combination of hardware sales (the fenoTRACK device) and consumables (test strips), with potential subscription or service revenue for continuous monitoring and clinical decision support delivered through the app. Go-to-market is structured as enterprise field sales targeting four distinct segments: patients (direct, at-home monitoring), clinicians (pulmonologists, allergists, primary care), healthcare payers and insurers (cost reduction via early intervention), and pharmaceutical companies (companion diagnostics and clinical trial support). The company is headquartered in Lowell, Massachusetts with an operational office in Fishers, Indiana.
Biometry is venture-backed and pre-revenue. To date it has raised approximately $8.99 million in disclosed equity financing, including a $5 million oversubscribed Seed round led by Dexcom Ventures in November 2024 with participation from CareSource Indiana, Elevate Ventures, and New York Angels, plus a subsequent ~$3.99 million SEC Form D exempt offering filed in December 2025. The company has also received non-dilutive capital from the Massachusetts Manufacturing Innovation Initiative ($626,000, July 2024), MassChallenge accelerators, and selection into the 2026 Blue Cross Blue Shield of Massachusetts / MassChallenge Health Equity Business Accelerator. Leadership includes alumni of Quanterix, Roche/Ventana, Novartis, QIAGEN, Becton Dickinson, and TheraSense, supported by clinical advisors including Professor Ian Pavord of Oxford, the second-highest cited asthma researcher worldwide.
Biometry firmographics
Firmographics- Name
- Biometry
- Legal name
- BIOMETRY Inc.
- Website
- https://mybiometry.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biometry (myBiometry) is a US-based health technology company developing fenoTRACK, a pre-commercial at-home FeNO breath test device with companion app and predictive engine, targeting asthma and COPD patients, clinicians, payers, and pharmaceutical companies.
- Ownership category
- akta.pro rank
Biometry industry classification
Industry- Product category
- Respiratory Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
- akta.pro secondary industries
- Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH), COPD & Chronic Bronchitis Management (HLAKANAE), Asthma & Airway Disease Specialty Care (HLAKAAAC), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)
Keywords
Where Biometry is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Biometry business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- fenoTRACK Device and Test Strips: The company is developing a medical device (fenoTRACK) consisting of a portable device, test strips, and mobile app. Revenue will likely come from hardware sales (device) combined with consumable sales (test strips) for ongoing monitoring. Products are currently under development and have not yet been cleared by the FDA.
- Remote Monitoring Services: Potential subscription or service model for continuous monitoring, data analytics, and clinical decision support delivered through the app platform to patients, clinicians, and healthcare payers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Biometry product offering
Product offeringCore offering
Biometry develops fenoTRACK, a portable, non-invasive breath diagnostic system comprising a handheld sensor device, single-use test strips, and a companion mobile app. The device measures fractional exhaled nitric oxide (FeNO) to quantify type 2 airway inflammation in asthma and COPD patients, and feeds that data into a prediction engine that builds personalized risk models to predict exacerbations up to 20 days in advance. The product is currently under development and pending FDA regulatory clearance.
Product overview
myBiometry offers a unified product ecosystem centered on fenoTRACK — a medical device system comprising a handheld sensor device, single-use test strips, and a companion mobile application. The system enables at-home measurement of fractional exhaled nitric oxide (FeNO) as a biomarker for airway inflammation. The companion app collects clinical and environmental risk factors, which feed into the proprietary myBiometry Prediction Engine that generates personalized, predictive risk models for each patient. The platform delivers actionable insights and guideline-based self-management education to empower patients to prevent asthma and COPD attacks. The product is currently under development and pending FDA regulatory clearance.
Differentiator
Problem solved
Functional benefit
Brands
- fenoTRACK: Portable, non-invasive breath test device that measures type 2 airway inflammation via fractional exhaled nitric oxide (FeNO) for asthma and COPD patients
Products and services
- fenoTRACK A portable, non-invasive breath diagnostic system for asthma and COPD patients that measures fractional exhaled nitric oxide (FeNO) via a patented handheld sensor and disposable test strips to detect type 2 airway inflammation, combined with a mobile app that aggregates clinical and environmental risk factors into a prediction engine for early detection of exacerbations up to 20 days in advance.
Quantifiable outcome
- Early detection up to 20 days in advance
- +4 more outcomes
Companies that use Biometry
Customer profileSegments4 records
Ideal customer profiles4 records
Biometry technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Biometry partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MassChallenge / Blue Cross Blue Shield of MassachusettscoremyBiometry was selected as one of five startups for the 2026 Health Equity Business Accelerator program in Boston. The program provides each startup with a $50,000 grant and three months of tailored support to address health inequities. Blue Cross Blue Shield of Massachusetts and MassChallenge jointly run this accelerator.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Biometry competitors and assessment
Company assessmentOthers
- AstraZeneca: AstraZeneca markets Dupixent (with Sanofi/Regeneron) and other Type 2 inflammation biologics that target the same patient population Biometry serves. Represents a potential pharma partner for companion diagnostics and clinical trial stratification using fenoTRACK.
- Quanterix: Quanterix is an ultra-sensitive biomarker detection platform used in respiratory and immunology research. Biometry's CPO previously served as Sr. Director of Engineering at Quanterix, and the companies share a diagnostics/customer base in respiratory biomarker research.
Direct peers
- Bedfont Scientific: Bedfont manufactures the NObreath FeNO monitor, a direct competitor in point-of-care and clinical FeNO measurement. Comparable in target customer (pulmonologists, allergists, PCPs) and clinical use case.
- Bosch Healthcare Solutions: Bosch's Vivatmo pro and Vivatmo me FeNO devices compete directly in the FeNO monitoring category. Backed by Bosch's industrial scale, they represent a well-resourced incumbent in the same product category.
- NIOX Group: NIOX (formerly Circassia/Aerocrine) is the global leader in FeNO measurement with NIOX VERO and NIOX MINO devices used in pulmonary clinics. It is the most direct competitor to Biometry's fenoTRACK, though Biometry differentiates on at-home use and predictive analytics.
Emerging players
- FindAir: FindAir offers a smart inhaler add-on and respiratory health app for asthma and COPD patients. Comparable in targeting at-home digital respiratory monitoring, though focused on inhaler-based rather than FeNO biomarker data.
- Propeller Health (ResMed): Propeller (acquired by ResMed) provides digital respiratory health tools, including smart inhaler sensors and adherence/predictive analytics for asthma and COPD. Overlaps with Biometry on the digital monitoring and prediction layer but uses a different sensor modality.
- Adherium: Adherium develops smart inhaler sensors and a digital respiratory platform focused on medication adherence and remote monitoring for asthma and COPD. Comparable target patient population and digital health model.
Broad incumbents
- Philips Respironics: Philips Respironics is a major incumbent in respiratory care, offering nebulizers, oxygen therapy, ventilators, and sleep diagnostics. Touches the same patient population as Biometry through broader respiratory care channels.
- ResMed: ResMed is a global leader in respiratory and sleep medicine devices and the parent of Propeller Health. Provides broad respiratory care infrastructure across sleep apnea, COPD, and asthma — overlapping with Biometry in COPD management and remote monitoring.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Biometry social profiles
Digital presenceBiometry financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biometry leadership team
Management profileNumber of profiles
Profiles14 records
Biometry funding detail
Funding detailFunding overview
Funding rounds8 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biometry M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biometry
What does Biometry do?
Biometry develops fenoTRACK, a portable, non-invasive breath diagnostic system comprising a handheld sensor device, single-use test strips, and a companion mobile app. The device measures fractional exhaled nitric oxide (FeNO) to quantify type 2 airway inflammation in asthma and COPD patients, and feeds that data into a prediction engine that builds personalized risk models to predict exacerbations up to 20 days in advance. The product is currently under development and pending FDA regulatory clearance.
Is Biometry a public or private company?
Biometry is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biometry founded?
Biometry was founded in 2017. It employs 11 to 50 people.
Where is Biometry based?
Biometry is headquartered in Boston, United States, in the North America region.
How does Biometry make money?
Two revenue lines are on record. fenoTRACK Device and Test Strips are the primary driver. The others are remote Monitoring Services.
Who are Biometry's main competitors?
Others on record are AstraZeneca and Quanterix. Direct peers are Bedfont Scientific, Bosch Healthcare Solutions and NIOX Group. Emerging players are FindAir, Propeller Health (ResMed) and Adherium. Broad incumbents are Philips Respironics and ResMed.
Does Biometry have an API?
No public API is recorded for Biometry.
What industry is Biometry in?
Biometry's product category is Respiratory Diagnostic Devices. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHAGAH, Pulmonary Function Testing (PFT) & Spirometry Equipment. Its NAICS code is 334510 and its SIC code is 3841.